EFS analysis. Kaplan-Meier curves of EFS after treatment with vorinostat-R-EPOCH and R-EPOCH alone for all study-eligible patients with aggressive HIV-NHL (n = 86) (A); all DLBCL (n = 61) (B); non-GCB (n = 26) (C) and GGB (n = 34) DLBCL subtypes (1 case was not classified) (D); and PBL (n = 15) (E) and PEL (n = 7) (F).